Use the hyperlinks, where available to access additional clinical trial information.
A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients With High Risk RetroPeritoneal Sarcoma (RPS)
European Organisation for Research and Trearment of Cancer (EORTC)
Eligible participants will be randomly allocated to either the Standard Arm or the Experimental Arm. In the Standard Arm, participants will receive large en-bloc curative-intent surgery within 4 weeks following randomisation. In the Experimental Arm, participants will receive 3 cycles of neoadjuvant chemotherapy starting within 2 weeks following randomisation. People with liposarcoma will receive ADM (doxorubicin) 75mg/m2 (or the equivalent EpiADM 120mg/m2) + ifosfamide 9g/m3 every 3 weeks. People with leiomyosarcoma will receive ADM 75mg/m2 + DTIC (dacarbazine) 1g/m2 every 3 weeks. Following this, participants in the experimental arm will be re-assessed to determine whether surgery can proceed. If yes, curative-intent surgery will be performed within 3-6 weeks of last cycle of chemotherapy.